

The Premier Event for Building Drug Discovery Innovations & Collaborations

MONDAY
September 28

SYMPOSIA

- Induced Proximity-Based Drug Discovery
- Generative AI/Machine Learning-Driven Drug Design

TRAINING SEMINARS

- Know Your GPCR Molecule: Four Most Common Causes of Drug Candidate Failure
- Drug Exposure at the Target: The Role of ADME and Pharmacokinetics
- AI-Driven Design of Biologics

SHORT COURSES

- MORNING
- LUNCHEON WORKSHOPS
(sponsorship opportunities available)
- AFTERNOON 2:30-4:30
- EVENING

SMALL MOLECULE DRUG DISCOVERY **TUESDAY** September 29 — **THURSDAY** October 1

EMERGING DRUG TARGETS

- Cancer: Degradar & Chemical Approaches
- Autoimmunity & CNS: PPI Modulators
- Obesity: Bound Peptides & Beyond

NOVEL DRUG MODALITIES

- PROTACs, Molecular Glues and Proximity Inducers
- Peptides, Covalent Drugs & Conjugated Therapies
- AI/ML-designed and Synthetic Biology-enabled Drug Entities

LEAD GENERATION STRATEGIES

- AI, Structural Validation and Novel Screening
- Intelligent Modalities and Precision Engineering
- Targeting Membrane Proteins and Restrictive Barriers

INNOVATIVE DISCOVERY TECHNOLOGIES

- AI/ML & Tools for Target Identification & Validation
- Proteomics & Functional Genomics Screening
- AI/ML for Early Screening & Predictions
- 3D Models & NAMs for Drug Development (PCL)

PLENARY KEYNOTE **WEDNESDAY** September 30

BIOLOGICS & RADIOLIGANDS **TUESDAY** September 29 — **THURSDAY** October 1

ANTIBODIES AGAINST CHALLENGING TARGETS

- AI, Structural Validation and Novel Screening
- Intelligent Modalities and Precision Engineering
- Targeting Membrane Proteins and Restrictive Barriers

NEXT-GENERATION CONJUGATES

- Novel Target Discovery and Validation
- Linker Chemistry and Conjugation Methods
- Emerging Payloads and Modalities

RADIOLIGAND THERAPIES

- Engineering Optimized Ligands, Linkers, and Radionuclides
- New Targets, Mechanisms, and Combinations
- Personalized Dosimetry and Theranostics